Company Profile // Digital Health // Boston, MA
Neuroglee Health
Reimagining dementia care - moving expert cognitive support out of the clinic waiting room and into the home, for patients and the families who care for them.
Reimagining dementia care - moving expert cognitive support out of the clinic waiting room and into the home, for patients and the families who care for them.
For most families, a dementia diagnosis is a door that closes. The appointment ends, the paperwork is filed, and the hardest years - the ones that require the most support - begin with the least of it. Neuroglee Health, a Boston-based digital health company founded in 2020, was built to redesign exactly that stretch of the journey.
Rather than a single app or a single clinic, Neuroglee runs a virtual, interdisciplinary care team - advanced practice nurses, licensed social workers, pharmacists and care navigators, supervised by neurologists and geriatric psychiatrists - and wraps it in evidence-based digital tools. The model follows a patient from mild cognitive impairment through late-stage dementia, and it treats the family care partner as someone who needs support too, not just an observer in the room.
The company works with Mayo Clinic on its Neuroglee Connect platform and was selected for the U.S. government's GUIDE Model, a value-based payment program designed to make comprehensive dementia care reach Medicare beneficiaries - at no cost to the families enrolled.
Neuroglee delivers longitudinal, team-based cognitive and dementia care remotely, so families do not have to choose between expert support and staying home.
Traditional memory care often ends the day the diagnosis is given. Families are left with limited clinical follow-up, little caregiver support, and rising costs as symptoms progress.
Medicare beneficiaries living with mild cognitive impairment through late-stage dementia - reached through health systems and neurology groups - and the family members caring for them.
Early detection, remote monitoring, proactive symptom management and 24/7 wraparound support, paid for through value- and risk-based arrangements rather than out of a family's pocket.
"A milestone in our mission to lower the total cost of dementia care while improving outcomes, access, and experience for families."- Aniket Singh Rajput, Founder & CEO
A patient with dementia costs Medicare roughly three times more than a member without Alzheimer's or another dementia. Neuroglee's pitch to payers and risk-bearing entities: catch decline early, manage it continuously, and take cost out of the system while improving the years families have.
The value-based bet is that proactive, coordinated dementia care reduces avoidable crises - ER visits, hospitalizations, premature facility placement - which is where the money and the heartbreak concentrate. Neuroglee measures itself in both savings per member and quality of family life.
A virtual dementia and cognitive care platform developed with Mayo Clinic, guided by the principles of Mayo's HABIT (Healthy Action to Benefit Independence & Thinking) program - bringing clinic-grade cognitive rehabilitation into the home.
Since 2021Longitudinal, value-based dementia care under the CMS Innovation GUIDE Model, enrolling eligible Medicare beneficiaries at no cost to the patient or family - from early cognitive impairment through end-stage dementia.
2025Advanced practice nurses, licensed social workers, pharmacists and care navigators, supervised by neurologists and geriatric psychiatrists, offering 24/7 wraparound support for patients and care partners.
OngoingA prescription digital therapeutic for Alzheimer's disease using AI and machine learning, adaptive cognitive tasks and reminiscence therapy - personal images from a patient's past used to ease memory loss and lift mood.
Since 2021Alternatives range from in-person memory clinics and neurology practices to a new wave of digital dementia and brain-health companies such as Ceresti Health, Rippl Care and Isaac Health. Neuroglee's distinction is combining a virtual clinical team, an academic-grade care model, and value-based payment in one program.
Aniket Singh Rajput launches the company (as Neuroglee Therapeutics) in Singapore to build digital therapeutics for neurodegenerative disease.
Early funding backs development of the digital therapeutics platform.
Round led by Openspace Ventures and EDBI, with backing from pharma company Eisai; HQ relocates to Boston's digital-health hub.
Neuroglee Connect is developed with Mayo Clinic, extending the HABIT cognitive program into home-based care.
Selected for the CMS GUIDE Model and expands the Mayo Clinic collaboration to launch at-home value-based dementia care.
Led by Openspace Ventures and EDBI. Investors include Japanese pharmaceutical company Eisai, former Mundipharma CEO Raman Singh, and Biofourmis co-founders Kuldeep Singh Rajput and Wendou Niu.
Early capital to develop the digital therapeutics platform and validate the care model. Total funding to date: approximately $12.3M.
Rajput earned a PhD in Robotics & Intelligent Systems - focused on neuroscience and healthcare - from Nanyang Technological University Singapore in 2020, then set out to build evidence-based digital therapeutics and virtual care for neurodegenerative disease. His view of the field is direct: AI is needed to determine what modalities actually work best for each individual with mild cognitive impairment. Neuroglee was co-founded with Sundeep Krishna Mohan Badiga.
It delivers comprehensive, value-based at-home dementia and cognitive care, combining a virtual interdisciplinary clinical team with evidence-based digital tools to support patients and their family caregivers.
Neuroglee was founded in 2020 by Aniket Singh Rajput, who serves as Founder & CEO. It started in Singapore before moving its headquarters to Boston.
About $12.3M total, including a $10M Series A in 2021 led by Openspace Ventures and EDBI, with backing from Eisai and others.
Neuroglee co-developed the Neuroglee Connect platform with Mayo Clinic, based on Mayo's HABIT program, and in 2025 expanded the collaboration to deliver at-home dementia care and enroll GUIDE-eligible patients at Mayo locations.
Through the CMS GUIDE Model, eligible Medicare beneficiaries and their families are enrolled in Neuroglee's dementia care program at no cost to the patient or family.